Reuters logo
BRIEF-European Commission grants MolMed Conditional Marketing Authorisation for Zalmoxis
August 22, 2016 / 6:21 AM / a year ago

BRIEF-European Commission grants MolMed Conditional Marketing Authorisation for Zalmoxis

Aug 22(Reuters) - MolMed SpA :

* The European Commission grants a Conditional Marketing Authorisation (CMA) for Zalmoxis

* Zalmoxis is an immunogene therapy for the treatment of adult patients with high-risk haematological malignancies

Source text: www.1info.it

Further company coverage:

Gdynia Newsroom

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below